Novo Nordisk (NYSE:NVO) is facing challenges following its guidance cut, but its blockbuster drugs, Ozempic and Wegovy, continue to drive strong sales growth. Analysts see a 52% upside potential with a $70 target, signaling this pharma giant’s pullback could be a rare buying opportunity.
Stock prices used were the market prices of Nov. 10, 2025. The video was published on Nov. 12, 2025. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.
